Table 2 The ongoing clinical trials of ICIs in virus-associated cancers
From: Immune checkpoint inhibitors in the treatment of virus-associated cancers
Trial identifier | Phase | Study title | Treatment | Patients |
|---|---|---|---|---|
ICIs in HPV-associated cancers | ||||
NCT02054806 | I | Pembrolizumab (MK-3475) in participants with advanced solid tumors (KEYNOTE-28) | Pembrolizumab | Advanced solid tumors |
NCT01848834 | I | Pembrolizumab (MK-3475) in participants with advanced solid tumors (KEYNOTE-012) | Pembrolizumab | Advanced Solid Tumors |
NCT02488759 | I/II | Nivolumab, and nivolumab Combination Therapy in Virus-associated Tumors (CheckMate 358) | Nivolumab Ipilimumab | Virus-associated tumors |
NCT02314169 | II | Nivolumab with or without ipilimumab in treating patients with refractory metastatic anal canal cancer (NCI 9673) | Ipilimumab Nivolumab | R/M SCCA |
NCT02105636 | III | Trial of nivolumab vs therapy of investigator’s choice in recurrent or metastatic head and neck carcinoma (CheckMate 141) | Nivolumab | R/M HNC |
NCT02379520 | I | HPV-16/18 E6/E7-specific T lymphocytes in patients with relapsed HPV-associated cancers | Nivolumab | HPV-related cancers |
NCT03841110 | I | FT500 as monotherapy and in combination with immune checkpoint inhibitors in subjects with advanced solid tumors | Nivolumab Pembrolizumab Atezolizumab | Advanced solid tumors |
NCT03228667 | II | QUILT-3.055: ALT-803 in combination with PD-1/PD-L1 checkpoint inhibitor in patients with advanced cancer | Pembrolizumab Nivolumab Atezolizumab Avelumab | Advanced cancers |
NCT02890368 | I | Intratumoral injections of TTI-621 in subjects with relapsed and refractory solid tumors and mycosis fungoides | PD-1/PD-L1 Inhibitor | HPV-related malignant neoplasm |
NCT03735290 | I/II | ILIxadencel administered into tumors in combination with checkpoint inhibitor (CPI) in patients with advanced cancer (ILIAD) | Pembrolizumab | Advanced cancer |
NCT02632344 | II | Pembrolizumab for HPV-associated recurrent respiratory papilloma patients with laryngeal, tracheal, and/or pulmonary involvement | Pembrolizumab | HPV-associated papilloma patients |
NCT01693783 | II | Ipilimumab in treating patients with metastatic or recurrent human papilloma virus-related cervical cancer | Ipilimumab | R/M HPV-related cervical cancer |
ICIs in HBV/HCV-associated cancers | ||||
NCT01853618 | I | Tremelimumab with chemoembolization or ablation for liver cancer | Tremelimumab | Liver cancer |
NCT01658878 | I/II | Nivolumab or nivolumab in combination with other agents in patients with advanced liver cancer (CheckMate040) | Nivolumab Ipilimumab | Advanced liver cancer |
NCT03841110 | I | FT500 as monotherapy and in combination with ICIs in subjects with advanced solid tumors | FT500 Nivolumab Pembrolizumab Atezolizumab | Advanced solid tumors (HCC) |
NCT03228667 | II | QUILT-3.055: a study of ALT-803 in combination with PD-1/PD-L1 checkpoint inhibitor in patients with advanced cancer | Pembrolizumab Nivolumab Atezolizumab Avelumab | Advanced cancer |
NCT03419481 | II | Pembrolizumab in patients with HBV-related HCC | Pembrolizumab | HBV-related HCC |
NCT02402699 | II | Ipilimumab 60-month pharmacovigilance protocol for advanced melanoma patients who are hepatitis B and/or hepatitis C virus positive in Taiwan (Yervoy RMP) | Ipilimumab | Melanoma (HBV/HCV positive) |
ICIs in EBV-associated cancers | ||||
NCT02339558 | II | Nivolumab in treating patients with recurrent and/or metastatic NPC | Nivolumab | R/M NPC |
NCT02054806 | I | Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-028/KEYNOTE-28) | Pembrolizumab | Advanced solid tumors |
NCT01848834 | I | Study of pembrolizumab (MK-3475) in participants with advanced solid tumors (MK-3475-012/KEYNOTE-012) | Pembrolizumab | Advanced solid tumors |
NCT02488759 | I/II | An investigational immuno-therapy study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy in virus-associated tumors (CheckMate358) | Nivolumab Ipilimumab | Virus-associated tumors |
NCT03258567 | II | Nivolumab in EBV-positive lymphoproliferative disorders and EBV-positive NHL | Nivolumab | EBV-positive lymphoproliferative disorders EBV-positive NHL |
NCT02973113 | I | Combining nivolumab with Epstein-Barr virus-specific T cells (EBVSTS) in relapsed/refractory EBV-positive lymphoma patients (PREVALE) | Nivolumab | EBV-positive lymphoma |
NCT03038672 | II | Nivolumab with or without varlilumab in treating patients with relapsed or refractory aggressive B cell lymphomas | Nivolumab Varlilumab | Aggressive B cell lymphomas (EBV-positive) |
NCT03015896 | I/II | Nivolumab and lenalidomide in treating patients with relapsed or refractory non-Hodgkin or Hodgkin lymphoma | Nivolumab | NHL or HL |
NCT03267498 | II | Nivolumab + chemoradiation in stage II–IVB nasopharyngeal carcinoma (NPC) | Nivolumab Chemoradiation | NPC |
NCT02834013 | II | Nivolumab and ipilimumab in treating patients with rare tumors | Nivolumab Ipilimumab | NPC |
NCT03427827 | III | Adjuvant PD-1 antibody in locoregionally advanced NPC after chemoradiotherapy | PD-1 antibody | NPC |
NCT03390738 | II | Nivolumab as treatment for recurrent/metastatic NPC after failing 2 lines or more previous chemotherapy | Nivolumab | R/M NPC |
NCT03769467 | I/II | Tabelecleucel in combination with pembrolizumab in subjects with EBV+ NPC (ATA129-NPC-202) | Pembrolizumab | EBV-positive NPC |
NCT03586024 | I/II | Pembrolizumab in patients with relapsed or refractory extranodal NK/T cell lymphoma (ENKTL), nasal type, and EBV-associated diffuse large B cell lymphomas | Pembrolizumab | EBV-associated diffuse large B cell lymphomas |
NCT03257163 | II | Pembrolizumab, capecitabine, and radiation therapy in treating patients with mismatch repair-deficient and EBV-positive gastric cancer | Pembrolizumab | EBV-positive GC |
NCT03544099 | II | Pembrolizumab for nasopharyngeal carcinoma patients with detectable plasma Epstein-Barr virus DNA | Pembrolizumab | EBV-positive NPC |
NCT03813394 | I/II | Bevacizumab and pembrolizumab combination in EBER-ISH positive NPC (2018/00947) | Pembrolizumab | NPC |
NCT03160079 | I/II | Blinatumomab and pembrolizumab for adults with relapsed/refractory B cell acute lymphoblastic leukemia with high marrow lymphoblasts | Pembrolizumab | Relapsed/refractory B cell ALL |
NCT02950220 | I | Pembrolizumab and ibrutinib in treating patients with relapsed or refractory non-Hodgkin lymphoma | Pembrolizumab | Relapsed or refractory NHL |
NCT03491345 | II | K-basket, avelumab, biomarker-driven, advanced solid tumor | Avelumab | EBV-positive mutation tumor |
NCT02875613 | II | Avelumab for recurrent/metastatic nasopharyngeal cancer | Avelumab | R/M NPC |
NCT03735290 | I/II | Evaluate the safety and effectiveness of ILIxadencel administered into tumors in combination with checkpoint inhibitor (CPI) in patients with advanced cancer | Pembrolizumab | Advanced cancer |
ICIs in virus-associated cancers (HIV, HTLV, HHV-8) | ||||
NCT02408861 | I | Ipilimumab and nivolumab in advanced HIV-associated solid tumors with expansion cohorts in HIV-associated solid tumors and a cohort of HIV-associated classical Hodgkin lymphoma | Nivolumab Ipilimumab | Advanced HIV-associated solid tumors |
NCT03316274 | I | Evaluate the safety, feasibility, and immunologic correlatives of intra-lesional nivolumab therapy for limited cutaneous Kaposi sarcoma | Nivolumab | Limited cutaneous Kaposi sarcoma |
NCT03367754 | I | A single dose of pembrolizumab in HIV-infected people | Pembrolizumab | HIV-infected people |
NCT02595866 | I | Pembrolizumab in treating patients with HIV and relapsed, refractory, or disseminated malignant neoplasms | Pembrolizumab | Patients with HIV and malignant neoplasms |
NCT03239899 | I | PD-1 inhibition to determine CNS reservoir of HIV-infection | Pembrolizumab | HIV infection |
NCT03767465 | Observational | Treatment with ICIs of HIV-infected subjects with cancer (PembroHIV) | ICIs | HIV-infected subjects with cancer |
NCT03075553 | II | Nivolumab in treating patients with relapsed or refractory peripheral T cell lymphoma | Nivolumab | Relapsed or refractory peripheral T cell lymphoma |
NCT02631746 | II | Nivolumab in treating patients with HTLV-associated T cell leukemia/lymphoma | Nivolumab | HTLV-associated T cell leukemia/lymphoma |
NCT03469804 | II | Phase II multicentric study of pembrolizumab in classic or endemic Kaposi’s sarcoma | Pembrolizumab | Classic or endemic Kaposi’s sarcoma |
NCT03038672 | II | Nivolumab with or without varlilumab in treating patients with relapsed or refractory aggressive B cell lymphomas | Nivolumab Varlilumab | Relapsed or refractory aggressive B cell lymphomas |
NCT03219671 | II | Nivolumab and ipilimumab in classical Kaposi sarcoma | Nivolumab Ipilimumab | Classic Kaposi sarcoma |